The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with
The patent applications, refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT), 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of
The patent applications are part of the company's commitment to offer patients safer and more effective treatments than those available today partly by strengthening its IP portfolio to broaden the therapeutic psychedelic toolbox for patients with mental health disorders that require transformative medicines, and developing treatments that offer synergy, efficacy and safety while reducing cost.
Clearmind has a broad IP footprint in the psychedelic space, with 51 patents in 15 utility patent families, of which twenty-six are granted patents in major jurisdictions like the US,
As part of the collaboration agreement between Clearmind and
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of 15 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol "CMND" and the
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
About
FORWARD-LOOKING STATEMENTS:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its commitment to offer patients safer and more effective treatments than those available today and the strengthening of its IP portfolio to broaden the therapeutic psychedelic toolbox for patients with mental health disorders that require transformative medicines and to develop treatments that offer synergy, efficacy and safety while reducing cost. In addition, the Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the
![](https://ml.globenewswire.com/media/YjU2ZjQ5NGUtMjJlYS00N2IyLWE3NWQtZGZkNjM5Mjc4ZjYxLTUwMDA4NjkzNA==/tiny/Clearmind-Medicine-Inc-.png)
2024 GlobeNewswire, Inc., source